Stratifying risks for adverse events when positioning therapies is critical. Younger patients with no cardiovascular risk factors are good candidates for JAK inhibitors.

Considering that adverse events to JAK inhibitors are dose dependent, the lowest effective dose should be used during the maintenance phase of treatment.

Even though novel, more selective JAK inhibitors potentially offer a better safety profile, long-term data are needed.